XML 29 R15.htm IDEA: XBRL DOCUMENT v3.20.4
Inventories
 12 Months Ended
Dec. 31, 2020
Inventory Disclosure [Abstract]  
Inventories INVENTORIES
The following table summarizes our Inventories:
December 31,
(in millions)20202019
Raw materials$1,080 $1,348 
Work in process976 170 
Finished goods958 549 
Total$3,014 $2,067 
Reported as:
Inventories$1,683 $922 
Other long-term assets1,331 1,145 
Total$3,014 $2,067 
Amounts reported as other long-term assets primarily consisted of raw materials as of December 31, 2020 and 2019. Total inventories at December 31, 2020 include fair value adjustments resulting from the Immunomedics acquisition which will be recognized in future periods. See Note 6. Acquisitions for additional information.
Inventory write down charges for the year ended December 31, 2020 were not material. During the year ended December 31, 2019, we recorded inventory write down charges of $649 million, of which $547 million was related to slow moving and excess raw material and work in process inventory primarily due to lower long-term demand for our HCV products. During the year ended December 31, 2018, we recorded inventory write down charges of $572 million, of which $440 million was related to excess raw materials primarily due to a sustained decrease in demand for Harvoni.